Literature DB >> 16614807

Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation.

Rogier M Determann, Julian L Millo, Chris S Garrard, Marcus J Schultz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16614807     DOI： 10.1007/s00134-006-0167-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome.

Authors:  A Günther; P Mosavi; S Heinemann; C Ruppert; H Muth; P Markart; F Grimminger; D Walmrath; B Temmesfeld-Wollbrück; W Seeger
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Protein C in pneumonia.

Authors:  G Choi; M J Schultz; M Levi; T van der Poll; J L Millo; C S Garrard
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

3.  Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.

Authors:  Ali A El Solh; Milapchand Bhora; Lilibeth Pineda; Alan Aquilina; Laurie Abbetessa; Eileen Berbary
Journal:  Intensive Care Med       Date:  2005-11-12       Impact factor: 17.440

4.  Procoagulant and fibrinolytic activity in ventilator-associated pneumonia: impact of inadequate antimicrobial therapy.

Authors:  Ali A El-Solh; Mifue Okada; Celestino Pietrantoni; Alan Aquilina; Eileen Berbary
Journal:  Intensive Care Med       Date:  2004-07-23       Impact factor: 17.440

5.  Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.

Authors:  M J Schultz; J Millo; M Levi; C E Hack; G J Weverling; C S Garrard; T van der Poll
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139
  5 in total
  8 in total

1.  Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients.

Authors:  Marina Marchetti; Patricia Gomez-Rosas; Laura Russo; Sara Gamba; Eleonora Sanga; Cristina Verzeroli; Chiara Ambaglio; Francesca Schieppati; Francesco Restuccia; Ezio Bonanomi; Marco Rizzi; Stefano Fagiuoli; Andrea D'Alessio; Grigorios T Gerotziafas; Luca Lorini; Anna Falanga
Journal:  Front Cardiovasc Med       Date:  2022-06-10

2.  4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.

Authors:  Anil Sapru; Helen Hansen; Temitayo Ajayi; Ron Brown; Oscar Garcia; HanJing Zhuo; Joseph Wiemels; Michael A Matthay; Jeanine Wiener-Kronish
Journal:  Anesthesiology       Date:  2009-05       Impact factor: 7.892

3.  PAI-1 inhibits neutrophil efferocytosis.

Authors:  Young-Jun Park; Gang Liu; Emmanuel F Lorne; Xia Zhao; Jing Wang; Yuko Tsuruta; Jaroslaw Zmijewski; Edward Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

4.  Elevated postischemic tissue injury and leukocyte-endothelial adhesive interactions in mice with global deficiency in caveolin-2: role of PAI-1.

Authors:  Yajun Liu; Meifang Wang; Derek Wang; William P Fay; Ronald J Korthuis; Grzegorz Sowa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-08       Impact factor: 4.733

5.  Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury.

Authors:  Anil Sapru; Martha A Q Curley; Sandra Brady; Michael A Matthay; Heidi Flori
Journal:  Intensive Care Med       Date:  2009-10-24       Impact factor: 17.440

Review 6.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

7.  Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study.

Authors:  Agnese Ozolina; Marina Sarkele; Olegs Sabelnikovs; Andrejs Skesters; Inta Jaunalksne; Jelena Serova; Talis Ievins; Lars J Bjertnaes; Indulis Vanags
Journal:  Front Med (Lausanne)       Date:  2016-11-28

Review 8.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.

Authors:  Claire S Whyte; Gael B Morrow; Joanne L Mitchell; Pratima Chowdary; Nicola J Mutch
Journal:  J Thromb Haemost       Date:  2020-06-03       Impact factor: 16.036
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.